Zacks Investment Research lowered shares of Cyclacel (NASDAQ:CYCC) from a buy rating to a hold rating in a research note released on Friday morning.
According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. “
Other research analysts also recently issued reports about the stock. HC Wainwright restated a buy rating on shares of Cyclacel in a research report on Thursday, March 29th. ValuEngine upgraded shares of Cyclacel from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
Several institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC bought a new position in shares of Cyclacel in the 4th quarter worth about $108,000. Two Sigma Investments LP bought a new stake in Cyclacel in the 4th quarter valued at about $122,000. Finally, Virtu Financial LLC lifted its position in Cyclacel by 69.5% in the 4th quarter. Virtu Financial LLC now owns 199,464 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 81,820 shares during the last quarter. Institutional investors own 6.58% of the company’s stock.
Cyclacel Company Profile
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel and related companies with MarketBeat.com's FREE daily email newsletter.